28 related articles for article (PubMed ID: 23010851)
1.
Dowty ME; Qiu R; Dantonio A; Niosi M; Doran A; Balesano A; Wright SW; Walker GS; Sharma R
Drug Metab Dispos; 2024 May; ():. PubMed ID: 38719744
[TBL] [Abstract][Full Text] [Related]
2. Federated learning framework integrating REFINED CNN and Deep Regression Forests.
Nolte D; Bazgir O; Ghosh S; Pal R
Bioinform Adv; 2023; 3(1):vbad036. PubMed ID: 37033467
[TBL] [Abstract][Full Text] [Related]
3. Tumor immune microenvironment and mutational analysis of tracheal adenoid cystic carcinoma.
Wang F; Xie X; Song M; Ji L; Liu M; Li P; Guan Y; Lin X; Qin Y; Xie Z; Zhang J; Ouyang M; Gu Y; Deng H; Xia X; Xin Y; Zhou C
Ann Transl Med; 2020 Jun; 8(12):750. PubMed ID: 32647675
[TBL] [Abstract][Full Text] [Related]
4. Metabolite Profiling in Anticancer Drug Development: A Systematic Review.
Muhamad N; Na-Bangchang K
Drug Des Devel Ther; 2020; 14():1401-1444. PubMed ID: 32308372
[TBL] [Abstract][Full Text] [Related]
5. A New Validated HPLC-MS/MS Method for Quantification and Pharmacokinetic Evaluation of Dovitinib, a Multi-Kinase Inhibitor, in Mouse Plasma.
AlRabiah H; Kadi AA; Aljohar HI; Attwa MW; Al-Shakliah NS; Attia SM; Mostafa GA
Drug Des Devel Ther; 2020; 14():407-415. PubMed ID: 32095071
[TBL] [Abstract][Full Text] [Related]
6. Dovitinib enhances temozolomide efficacy in glioblastoma cells.
Thanasupawat T; Natarajan S; Rommel A; Glogowska A; Bergen H; Krcek J; Pitz M; Beiko J; Krawitz S; Verma IM; Ghavami S; Klonisch T; Hombach-Klonisch S
Mol Oncol; 2017 Aug; 11(8):1078-1098. PubMed ID: 28500786
[TBL] [Abstract][Full Text] [Related]
7. Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials.
Dillon PM; Chakraborty S; Moskaluk CA; Joshi PJ; Thomas CY
Head Neck; 2016 Apr; 38(4):620-7. PubMed ID: 25487882
[TBL] [Abstract][Full Text] [Related]
8. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.
Wulkersdorfer B; Zeitlinger M; Schmid M
Clin Pharmacokinet; 2016 Jan; 55(1):47-77. PubMed ID: 26201307
[TBL] [Abstract][Full Text] [Related]
10. Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.
Dubbelman AC; Upthagrove A; Beijnen JH; Marchetti S; Tan E; Krone K; Anand S; Schellens JH
Cancer Chemother Pharmacol; 2012 Nov; 70(5):653-63. PubMed ID: 23010851
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.
Kim KB; Chesney J; Robinson D; Gardner H; Shi MM; Kirkwood JM
Clin Cancer Res; 2011 Dec; 17(23):7451-61. PubMed ID: 21976540
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
[TBL] [Abstract][Full Text] [Related]
13. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.
Escudier B; Grünwald V; Ravaud A; Ou YC; Castellano D; Lin CC; Gschwend JE; Harzstark A; Beall S; Pirotta N; Squires M; Shi M; Angevin E
Clin Cancer Res; 2014 Jun; 20(11):3012-22. PubMed ID: 24691021
[TBL] [Abstract][Full Text] [Related]
14. Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity.
Porta C; Giglione P; Liguigli W; Paglino C
Future Oncol; 2015; 11(1):39-50. PubMed ID: 25572783
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
